Huatai-PB Hang Seng Biotech ETF

159102

516930

520880

<p>In 2026, the business expansion transactions of China's innovative drugs continued to heat up, with 44 external licensing transactions occurring within the year, totaling over USD 53 billion, with an upfront payment of approximately USD 3.123 billion</p>

Wallstreetcn

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI BIOMEDICINE ETF

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Universal Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB CSI Hugangshen Innovative Drugs Industry ETF

Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng Biotech ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI Innovative Drugs Industry ETF

Guotai Hang Seng Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year

Huatai-PB Hang Seng Biotech ETF(513930.SH)

Chinese innovative drugs are making strong strides overseas, with total overseas licensing amounts exceeding 53 billion USD this year